Vascularized composite allotransplantation: current standards and novel approaches to prevent acute rejection and chronic allograft deterioration

Transplant International

Volumn 29, Issue 6, 2016, Pages 655-662

  Kueckelhaus, Maximilian ^a,b   Fischer, Sebastian ^a,c   Seyda, Midas ^a   Bueno, Ericka M ^a   Aycart, Mario A ^a   Alhefzi, Muayyad ^a   ElKhal, Abdallah ^a   Pomahac, Bohdan ^a   Tullius, Stefan G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c KLINIKUM LUDWIGSHAFEN   (Germany)

Author keywords

acute rejection; antibody mediated rejection; chronic rejection; composite tissue allotransplantation; immunosuppression; vascularized composite allotransplantation

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; BORTEZOMIB; CLOBETASOL; DEXAMETHASONE; ECULIZUMAB; IMMUNOGLOBULIN; MYCOPHENOLATE MOFETIL; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ANTIGEN PRESENTING CELL; BIOMICROSCOPY; CELL THERAPY; CHRONIC ALLOGRAFT DETERIORATION; CYTOMEGALOVIRUS INFECTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GRAFT FAILURE; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; NEPHROTOXICITY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; VASCULARIZED COMPOSITE ALLOTRANSPLANTATION;

EID: 84976534342     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12652     Document Type: Review

References (63)

1. Gilbert R. Transplant is successful with a cadaver forearm. Med Trib Med News 1964; 5: 20.
2. Gilbert R. Hand transplanted from cadaver is reamputated. Med Trib Med News 1964; 5: 23.
3. Murray JE. Organ transplantation (skin, kidney, heart) and the plastic surgeon. Plast Reconstr Surg 1971; 47: 425.
4. Tobin GR, Breidenbach WC III, Ildstad ST, Marvin MM, Buell JF, Ravindra KV. The history of human composite tissue allotransplantation. Transpl Proc 2009; 41: 466.
5. Diaz-Siso JR, Bueno EM, Sisk GC, Marty FM, Pomahac B, Tullius SG. Vascularized composite tissue allotransplantation – state of the art. Clin Transplant 2013; 27: 330.
6. Dubernard JM, Owen E, Herzberg G, et al. Human hand allograft: report on first 6 months. Lancet 1999; 353: 1315.
7. Shores JT, Brandacher G, Lee WP. Hand and upper extremity transplantation: an update of outcomes in the worldwide experience. Plast Reconstr Surg 2015; 135: 351e.
8. Fischer S, Kueckelhaus M, Pauzenberger R, Bueno EM, Pomahac B. Functional outcomes of face transplantation. Am J Transplant 2015; 15: 220.
9. Petruzzo P, Kanitakis J, Testelin S, et al. Clinicopathological findings of chronic rejection in a face grafted patient. Transplantation 2015, [Epub ahead of print].
10. Weissenbacher A, Hautz T, Zelger B, et al. Antibody-mediated rejection in hand transplantation. Transpl Int 2014; 27: e13.
11. Chandraker A, Arscott R, Murphy GF, et al. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant 2014; 14: 1446.
12. Duhamel P, Suberbielle C, Grimbert P, et al. Anti-HLA sensitization in extensively burned patients: extent, associated factors, and reduction in potential access to vascularized composite allotransplantation. Transpl Int 2015; 28: 582.
13. Cinamon U, Eldad A, Chaouat M, et al. A simplified testing system to evaluate performance after transplantation of human skin preserved in glycerol or in liquid nitrogen. J Burn Care Rehabil 1993; 14: 435.
14. Richters CD, Hoekstra MJ, van Baare J, du Pont JS, Kamperdijk EW. Immunogenicity of glycerol-preserved human cadaver skin in vitro. J Burn Care Rehabil 1997; 18: 228.
15. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant 2013; 13(Suppl. 3): 24; quiz.
16. Couzi L, Pitard V, Moreau JF, Merville P, Dechanet-Merville J. Direct and indirect effects of cytomegalovirus-induced gammadelta T cells after kidney transplantation. Front Immunol 2015; 6: 3.
17. Bonastre J, Landin L, Diez J, Casado-Sanchez C, Casado-Perez C. Factors influencing acute rejection of human hand allografts: a systematic review. Ann Plast Surg 2012; 68: 624.
18. Schneeberger S, Lucchina S, Lanzetta M, et al. Cytomegalovirus-related complications in human hand transplantation. Transplantation 2005; 80: 441.
19. Weissenbacher A, Hautz T, Pratschke J, Schneeberger S. Vascularized composite allografts and solid organ transplants: similarities and differences. Curr Opin Organ Transplant 2013; 18: 640.
20. Fischer S, Lian CG, Kueckelhaus M, et al. Acute rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant 2014; 19: 531.
21. Sinha I, Pomahac B. Split rejection in vascularized composite allotransplantation. Eplasty 2013; 13: e53.
22. Mathes DW, Randolph MA, Solari MG, et al. Split tolerance to a composite tissue allograft in a swine model. Transplantation 2003; 75: 25.
23. Kueckelhaus M, Fischer S, Lian CG, et al. Utility of sentinel flaps in assessing facial allograft rejection. Plast Reconstr Surg 2015; 135: 250.
24. Dvorak HF, Mihm MC Jr, Dvorak AM, Barnes BA, Manseau EJ, Galli SJ. Rejection of first-set skin allografts in man. The microvasculature is the critical target of the immune response. J Exp Med 1979; 150: 322.
25. Bhan AK, Mihm MC Jr, Dvorak HF. T cell subsets in allograft rejection. In situ characterization of T cell subsets in human skin allografts by the use of monoclonal antibodies. J Immunol 1982; 129: 1578.
26. Lian CG, Bueno EM, Granter SR, et al. Biomarker evaluation of face transplant rejection: association of donor T cells with target cell injury. Mod Pathol 2014; 27: 788.
27. Petruzzo P, Dubernard JM. The International Registry on Hand and Composite Tissue allotransplantation. Clin Transpl 2011; 247.
28. Diaz-Siso JR, Fischer S, Sisk GC, et al. Initial experience of dual maintenance immunosuppression with steroid withdrawal in vascular composite tissue allotransplantation. Am J Transplant 2015; 15: 1421.
29. Schneeberger S, Ninkovic M, Gabl M, et al. First forearm transplantation: outcome at 3 years. Am J Transplant 2007; 7: 1753.
30. Unadkat JV, Schneeberger S, Goldbach C, et al. Investigation of antibody-mediated rejection in composite tissue allotransplantation in a rat limb transplant model. Transpl Proc 2009; 41: 542.
31. Landin L, Cavadas PC, Ibanez J, Roger I, Vera-Sempere F. CD3+-mediated rejection and C4d deposition in two composite tissue (bilateral hand) allograft recipients after induction with alemtuzumab. Transplantation 2009; 87: 776.
32. Kaufman CL, Ouseph R, Blair B, et al. Graft vasculopathy in clinical hand transplantation. Am J Transplant 2012; 12: 1004.
33. Petruzzo P, Kanitakis J, Badet L, et al. Long-term follow-up in composite tissue allotransplantation: in-depth study of five (hand and face) recipients. Am J Transplant 2011; 11: 808.
34. Shores JT, Brandacher G, Lee WA. Hand and upper extremity transplantation: an update of outcomes in the worldwide experience. Plast Reconstr Surg 2015; 135: 351e.
35. Cendales LC, Kanitakis J, Schneeberger S, et al. The Banff 2007 working classification of skin-containing composite tissue allograft pathology. Am J Transplant 2008; 8: 1396.
36. Thione A, Cavadas PC, Lorca-Garcia C, Perez-Garcia A, Alfaro L. Late nail lesions rejection in a stable bilateral forearm allograft at 60 months posttransplantation. Ann Plast Surg 2014; 73: 612.
37. Tsutsui H, Ziada KM, Schoenhagen P, et al. Lumen loss in transplant coronary artery disease is a biphasic process involving early intimal thickening and late constrictive remodeling: results from a 5-year serial intravascular ultrasound study. Circulation 2001; 104: 653.
38. Kanitakis J, Karayannopoulou G, Lanzetta M, Petruzzo P. Graft vasculopathy in the skin of a human hand allograft: implications for diagnosis of rejection of vascularized composite allografts. Transpl Int 2014; 27: e118.
39. Mundinger GS, Munivenkatappa R, Drachenberg CB, et al. Histopathology of chronic rejection in a nonhuman primate model of vascularized composite allotransplantation. Transplantation 2013; 95: 1204.
40. Unadkat JV, Schneeberger S, Horibe EH, et al. Composite tissue vasculopathy and degeneration following multiple episodes of acute rejection in reconstructive transplantation. Am J Transplant 2010; 10: 251.
41. Menke J, Sollinger D, Schamberger B, Heemann U, Lutz J. The effect of ischemia/reperfusion on the kidney graft. Curr Opin Organ Transplant 2014; 19: 395.
42. Rao J, Lu L, Zhai Y. T cells in organ ischemia reperfusion injury. Curr Opin Organ Transplant 2014; 19: 115.
43. Lunsford KE, Barbas AS, Brennan TV. Recent advances in immunosuppressive therapy for prevention of renal allograft rejection. Curr Opin Organ Transplant 2011; 16: 390.
44. Slegtenhorst BR, Dor FJ, Rodriguez H, Voskuil FJ, Tullius SG. Ischemia/reperfusion injury and its consequences on immunity and inflammation. Curr Transplant Rep 2014; 1: 147.
45. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit 1995; 17: 584.
46. Schneeberger S, Khalifian S, Brandacher G. Immunosuppression and monitoring of rejection in hand transplantation. Tech Hand Up Extrem Surg 2013; 17: 208.
47. Khalifian S, Brazio PS, Mohan R, et al. Facial transplantation: the first 9 years. Lancet 2014; 384: 2153.
48. Chan KM, Gordon T, Zochodne DW, Power HA. Improving peripheral nerve regeneration: from molecular mechanisms to potential therapeutic targets. Exp Neurol 2014; 261: 826.
49. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335.
50. McAlister VC, Haddad E, Renouf E, Malthaner RA, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006; 6: 1578.
51. Schnider JT, Weinstock M, Plock JA, et al. Site-specific immunosuppression in vascularized composite allotransplantation: prospects and potential. Clin Dev Immunol 2013; 2013: 495212.
52. Kiwanuka H, Bueno EM, Diaz-Siso JR, Sisk GC, Lehmann LS, Pomahac B. Evolution of ethical debate on face transplantation. Plast Reconstr Surg 2013; 132: 1558.
53. Ali F, Dua A, Cronin DC. Changing paradigms in organ preservation and resuscitation. Curr Opin Organ Transplant 2015; 20: 152.
54. De Vlaminck I, Valantine HA, Snyder TM, et al. Circulating cell-free DNA enables noninvasive diagnosis of heart transplant rejection. Sci Transl Med 2014; 6: 241ra77.
55. Kueckelhaus MI, Fischer S, Kumamaru K, et al. Non-invasive monitoring of immune rejection in face transplant recipients. Plast Reconstr Surg 2015; in press.
56. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14: 272.
57. Schneeberger S, Gorantla VS, Brandacher G, et al. Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg 2013; 257: 345.
58. Leonard DA, Kurtz JM, Cetrulo CL Jr. Achieving immune tolerance in hand and face transplantation: a realistic prospect? Immunotherapy 2014; 6: 499.
59. Leonard DA, Kurtz JM, Mallard C, et al. Vascularized composite allograft tolerance across MHC barriers in a large animal model. Am J Transplant 2014; 14: 343.
60. Jindal R, Unadkat J, Zhang W, et al. Spontaneous resolution of acute rejection and tolerance induction with IL-2 fusion protein in vascularized composite allotransplantation. Am J Transplant 2015; 15: 1231.
61. Gharb BB, Rampazzo A, Altuntas SH, et al. Effectiveness of topical immunosuppressants in prevention and treatment of rejection in face allotransplantation. Transplantation 2013; 95: 1197.
62. Gajanayake T, Olariu R, Leclere FM, et al. A single localized dose of enzyme-responsive hydrogel improves long-term survival of a vascularized composite allograft. Sci Transl Med 2014; 6: 249ra110.
63. Solhjou Z, Athar H, Xu Q, Abdi R. Emerging therapies targeting intra-organ inflammation in transplantation. Am J Transplant 2015; 15: 305.